Apogee (APGE) Director Jennifer Fox Sells Shares in Merger

What Happened

• Jennifer A. Fox, a director of Apogee Therapeutics (APGE), disposed of 34,824 shares of Apogee common stock and had options (derivative securities) covering an additional 32,488 underlying shares cancelled/settled on 2026-09-03 pursuant to the Agreement and Plan of Merger with AbbVie.
• The filing lists no per-share sale price (N/A). The merger consideration was $135.11 per share; the 34,824 common shares are therefore worth roughly $4.71 million at that price. The options were cashed out under the merger terms for the excess of the $135.11 per-share consideration over each option’s exercise price (exact option payout not listed).

Key Details

• Transaction date: 2026-09-03 (all dispositions reported same day).
• Reported disposals: 34,824 common shares (stock) + options representing 10,370, 14,461 and 7,657 underlying shares (total 32,488 derivative shares); total underlying shares affected = 67,312.
• Price on Form 4: N/A; merger consideration: $135.11 per share (footnote).
• Shares owned after transaction: not specified in this filing.
• Footnotes: F1—dispositions pursuant to the Merger Agreement with AbbVie; F2—options were vested as of or became fully vested due to the merger; F3—each option was settled for cash equal to the excess of $135.11 minus the option exercise price.
• Timeliness: filing covers transactions dated 2026-09-03 and was reported on the same date (no late filing indicated).

Context

• These disposals were part of a corporate merger settlement, not open-market trades. Common shares were converted/sold under the merger terms; options were settled for cash (a cash-out of option value rather than an exercise-for-stock). Such merger-related dispositions are routine and reflect deal mechanics rather than an independent trade signal.